SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines

被引:11
|
作者
Khodavirdipour, Amir [1 ,2 ]
Keramat, Fariba [3 ]
Hashemi, Seyed Hamid [3 ]
Alikhani, Mohammad Yousef [4 ]
机构
[1] Univ Tabriz, Fac Nat Sci, Dept Biol, Tabriz, Iran
[2] St Johns Hosp, Div Human Genet, Dept Anat, Bangalore, Karnataka, India
[3] Hamadan Univ Med Sci, Fac Med, Dept Infect Dis, Hamadan, Iran
[4] Hamadan Univ Med Sci, Dept Microbiol, Hamadan, Iran
来源
AIMS MOLECULAR SCIENCE | 2020年 / 7卷 / 03期
关键词
COVID-19; vaccine; drug discovery; hrsACE2; ivermectin; famotidine; PNEUMONIA;
D O I
10.3934/molsci.2020013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
All species of coronavirus may cause infections in birds which is known to us since the 60s, but recently, from Nov 2019, the disease emerged in humans from the seafood market in Wuhan city. The previous viral outbreaks like SARS-CoV and MERS-CoV have also shown a greater mortality rate when transmitted to humans than other animals. An emerging concern in the 2019 novel coronavirus (SARS-CoV-2) is in terms of developing vaccine or discovery of new drugs to overcome the current viral pandemic. In this rapid-review, we aim to update the available data on coronavirus with the latest findings and achievements. So far, great steps have been taken such as hrsACE2 by a Swedish team from Karolinska Institute. Monash University announced the efficacy of Ivermectin to overcome COVID-19. The CRISPR/Cas13d as a new innovative therapeutics based might overcome the challenge of COVID-19. those strains of virus which lacking E protein-encoding regions are the perfect choice for vaccine development.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [31] The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development
    Dutta, Noton K.
    Mazumdar, Kaushiki
    Gordy, James T.
    JOURNAL OF VIROLOGY, 2020, 94 (13)
  • [32] Progress on the development of the SARS-CoV-2 vaccine and antibody drugs
    Xu S.
    Tang D.
    Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering, 2022, 39 (05): : 1059 - 1064
  • [33] SARS-CoV-2 vaccine development and how Brazil is contributing
    Kanno, Alex, I
    Barbosa, Mayra M. F.
    Moraes, Luana
    Leite, Luciana C. C.
    GENETICS AND MOLECULAR BIOLOGY, 2021, 44 (01)
  • [34] Development, Safety, Issues, and Challenges of the SARS-CoV-2 Vaccine
    Matsuzaka, Yasunari
    Yashiro, Ryu
    VACCINES, 2023, 11 (03)
  • [35] The way of SARS-CoV-2 vaccine development: success and challenges
    Dong, Yetian
    Dai, Tong
    Wang, Bin
    Zhang, Lei
    Zeng, Ling-Hui
    Huang, Jun
    Yan, Haiyan
    Zhang, Long
    Zhou, Fangfang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [36] The challenge of emerging SARS-CoV-2 mutants to vaccine development
    Rong Li
    Jun Liu
    Hui Zhang
    JournalofGeneticsandGenomics, 2021, 48 (02) : 102 - 106
  • [37] Vaccine development and technology for SARS-CoV-2: Current insight
    Cattel, Luigi
    Giordano, Susanna
    Traina, Sara
    Lupia, Tommaso
    Corcione, Silvia
    Angelone, Lorenzo
    La Valle, Giovanni
    De Rosa, Francesco G.
    Cattel, Francesco
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (03) : 878 - 896
  • [38] Development of DNA Vaccine Candidate against SARS-CoV-2
    Wang, Xingyun
    Rcheulishvili, Nino
    Cai, Jie
    Liu, Cong
    Xie, Fengfei
    Hu, Xing
    Yang, Nuo
    Hou, Mengqi
    Papukashvili, Dimitri
    He, Yunjiao
    Wang, Peng George
    VIRUSES-BASEL, 2022, 14 (05):
  • [39] The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
    Alturki, Sana O.
    Alturki, Sawsan O.
    Connors, Jennifer
    Cusimano, Gina
    Kutzler, Michele A.
    Izmirly, Abdullah M.
    Haddad, Elias K.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [40] SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
    Baay, Marc
    Lina, Bruno
    Fontanet, Arnaud
    Marchant, Arnaud
    Saville, Melanie
    Sabot, Philippe
    Duclos, Philippe
    Vandeputte, Joris
    Neels, Pieter
    BIOLOGICALS, 2020, 66 : 35 - 40